ProCE Banner Activity

CME

Neuregulin-1 (NRG1): An Emerging Tumor-Agnostic Target

Text Module

Learn how experts detect and treat NRG1 fusion–positive solid tumors in this interactive text module with expert perspectives from Stephen V. Liu, MD, and Ryma Benayed, PhD, on applying emerging research to biomarker testing and treatment strategies for patients with NRG1 fusion–driven cancers.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: February 02, 2022

Expiration: February 01, 2023

No longer available for credit.

Share

Faculty

Ryma Benayed

Ryma Benayed, PhD

Associate Attending
Department of Pathology
Director, Clinical NGS Laboratory
Molecular Dx Service
Memorial Sloan Kettering Cancer Center
New York, New York

Stephen Liu

Stephen Liu, MD

Assistant Professor of Medicine
Department of Medical Oncology
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Elevation Oncology

Partners

American Society for Clinical Pathology

ProCE Banner

Target Audience

This educational program is intended for oncologists, pathologists, and other healthcare professionals who treat patients with NRG1 fusion–driven cancers.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the role of NRG1 in normal human biology
  • Delineate the role of NRG1 fusions in oncogenesis
  • State the frequency of NRG1 fusions overall and in specific organs or cancer types
  • Prioritize the use of testing methods that can detect both known and unique NRG1 fusions
  • Describe the agents currently targeting NRG1 in terms of known efficacy and safety profiles
  • List the clinical trial inclusion and exclusion criteria for ongoing trials of NRG1-targeting agents

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Ryma Benayed, PhD

Associate Attending
Department of Pathology
Director, Clinical NGS Laboratory
Molecular Dx Service
Memorial Sloan Kettering Cancer Center
New York, New York

Ryma Benayed, PhD, has disclosed that she has received consulting fees from Hitachi, Loxo Oncology, and Roche Dx and fees for non-CME/CE services from Illumina.

Stephen Liu, MD

Assistant Professor of Medicine
Department of Medical Oncology
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

Stephen V. Liu, MD, has disclosed that he has received consulting fees from Amgen, AstraZeneca, BeiGene, Blueprint, Bristol-Myers Squibb, Daiichi Sankyo, Eisai, Elevation Oncology, Genentech/Roche, Gilead Sciences, Guardant Health, Janssen, Jazz, Lilly, Merck/MSD, Novartis, Regeneron, Takeda, and Turning Point Therapeutics and funds for research support (paid to his institution) from Alkermes, Bayer, Blueprint, Bristol-Myers Squibb, Elevation Oncology, Genentech, Lilly, Merck, Merus, Pfizer, Rain Therapeutics, RAPT, and Turning Point Therapeutics.

Staff Disclosure

Staff

Kristen Morrow, PhD

Editorial Contributor

Kristen Morrow, PhD, has no relevant conflicts of interest to report.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has no relevant conflicts of interest to report.

Kemi Obajimi, PhD

Scientific Director

Kemi Obajimi, PhD, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Kristen Rosenthal, PhD

Clinical Editor

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from February 02, 2022, through February 01, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this program is to improve the knowledge and competence of learners to incorporate developing clinical trial research and emerging novel agents into patient-centered therapies in the management of patients with NRG1 fusion–driven tumors.